EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance

Gerard Gurumurthy, Jenna Fielding, Philip Crea, Durga A K Kanigicherla

Nephron · 13.06.2026 · 1-8

DOI: 10.1159/000553058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron, online erschienen am 13.06.2026. Verfasst von Gerard Gurumurthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Kidney Diseases, Paraproteinemias. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monoclonal gammopathy of renal significance (MGRS) is a rare group of renal disorders caused by monoclonal immunoglobulins from non-malignant B-cell or plasma cell clones, with distinct amyloid (MGRS-A) and non-amyloid (MGRS-NA) subtypes. Although these are often grouped together, whether they share similar clinical phenotypes and outcomes is uncertain. We therefore examined similarities and differences between these subtypes in a contemporary real-world cohort.

Methods

We performed a single-centre retrospective evaluation of 17 biopsy-confirmed MGRS patients (10 MGRS-A, 7 MGRS-NA). Baseline parameters, treatment exposure, renal and haematologic responses, survival, and relapse were analysed descriptively with exploratory subgroup comparisons.

Results

MGRS-NA patients presented with significantly worse baseline renal function (median estimated glomerular filtration rate 18.0 mL/min/1.73 m2 vs. 49.0 mL/min/1.73 m2 in MGRS-A, p < 0.05) and progressed faster to dialysis (p < 0.01). Haematologic responses (≥VGPR) were achieved in 57.1% of MGRS-NA and 50% of MGRS-A patients, but these did not significantly correlate with renal improvement. Survival was similar between groups, with deaths in 28.6% of MGRS-NA and 20% of MGRS-A. Relapse occurred in 47.1% of patients, with median times of 51 months in MGRS-NA and 69 months in MGRS-A. Treatment, primarily bortezomib-based chemotherapy, was associated with toxicities (94.1%), yet renal responses remained limited.

Conclusion

The findings highlight the poor prognosis and rapid renal decline in MGRS-NA. We highlight the need for early diagnosis and an integrated renal-haematologic service to improve outcomes in this rare population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney DiseasesParaproteinemiasHumansFemaleRetrospective StudiesMaleAgedMiddle AgedTreatment OutcomeAmyloidosisAged, 80 and over

Stichwörter der Autor:innen

AmyloidosisMGUSMonoclonal gammopathy of renal significance

Autor:innen und Institutionen

  • The University of Manchester, Manchester, UK.
  • Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
  • Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK, durga.kanigicherla@mft.nhs.uk.
  • Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, UK, durga.kanigicherla@mft.nhs.uk.

Zitieren

APA

Gurumurthy, G., Fielding, J., Crea, P., & Kanigicherla, D. A. K. (2026). Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance. Nephron, 1-8. https://doi.org/10.1159/000553058

Vancouver

Gurumurthy G, Fielding J, Crea P, Kanigicherla DAK. Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance. Nephron. 2026:1-8. doi:10.1159/000553058

BibTeX
@article{Gurumurthy2026,
  author = {Gurumurthy, Gerard and Fielding, Jenna and Crea, Philip and Kanigicherla, Durga A K},
  title = {Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance},
  journal = {Nephron},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000553058}
}
Kostenlos starten →